Response to a case report: Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab-Reference-Cited by-同舟云学术

Response to a case report: Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab

Published:2021-01-04 Issue:2 Volume:9 Page:
ISSN:2051-3380
Container-title:Respirology Case Reports
language:en
Short-container-title:Respirology Case Reports

Author:

Requena Gema¹^ORCID,Roufosse Florence²,Baylis Lee D.³,Steinfeld Jonathan⁴

Affiliation:

1. Epidemiology, Value Evidence and Outcomes Global R&D, GSK London UK

2. Department of Internal Medicine, Hôpital Erasme Université Libre de Bruxelles Brussels Belgium

3. Respiratory Medical Franchise GSK Research Triangle Park NC USA

4. Respiratory Research & Development GSK Collegeville PA USA

Funder

GlaxoSmithKline

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/rcr2.707

Reference3 articles.

1. Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab

2. FDA.2020.Nucala US prescribing information.https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL.PDF(accessed 15 October 2020).

3. Eosinophil's Role Remains Uncertain as Anti–Interleukin-5 only Partially Depletes Numbers in Asthmatic Airway

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reply to Correspondence: Response to a case report: idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab;Respirology Case Reports;2021-01-07